CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)

Active
Yes
Status
Posted
Published Date
June 7th, 2024
Close Date
September 23rd, 2026
Opportunity No.
RFA-ES-24-005

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health (NIH) has posted a grant opportunity titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)". This grant aims to support research that seeks to understand the mechanisms of chemical toxicity and identify potential molecular/genetic targets that reduce the acute effects of chemical threat agents on the eyes and lungs. The discoveries made through this research can lead to the exploration of therapeutic countermeasures through early stage development efforts supported by the Countermeasures Against Chemical Threats (CounterACT) NIH-wide program, which is a component within the Chemical Countermeasures Research Program (CCRP). The grant does not require cost sharing or matching and falls under the category of funding activity related to health. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territories or Possessions. Non-domestic (non-U.S.) entities and components are not eligible to apply. The grant opportunity will close on September 23, 2026, and more information can be found at the following link: http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-24-005.html. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Description

The purpose of this Notice of Funding Opportunity (NOFO) is to support research seeking to understand mechanisms of chemical toxicity and to identify potential molecular/genetic targets that reduce acute effects of chemical threat agents that affect the eyes and lungs. These discoveries can lead to exploration of therapeutic countermeasures through early stage development efforts supported by the Countermeasures Against Chemical Threats (CounterACT) NIH-wide program, a component within the Chemical Countermeasures Research Program (CCRP).

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)". This grant aims to support translational exploratory/developmental research projects that advance the discovery of novel treatment strategies, specifically medical countermeasures (MCMs), for addressing serious morbidity and mortality caused by acute exposure to highly toxic chemical threats. Chemical threats encompass toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and ultra-potent synthetic (UPS) opioids. The grant supports translational research that involves preliminary efficacy and/or early preclinical development studies to discover and validate novel molecular entities or biologics as candidate MCMs. In addition to novel agents, the grant also encourages the exploration of new treatment strategies, such as repurposing already FDA-approved products or combinations of interventions based on established mechanisms of action. Projects funded by this grant are expected to generate preliminary data that will facilitate the development of competitive applications for further support from the NIH CounterACT Cooperative Agreement program and other related initiatives. The grant does not require cost sharing or matching requirements and falls under the category of funding activity related to health. The opportunity is posted on grants.gov and is classified as discretionary. The CFDA number associated with this grant is 93.867. The eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territories or Possessions. Non-domestic (non-U.S.) entities (foreign organizations) and non-domestic components of U.S. organizations are not eligible to apply. The grant has a closing date of May 30, 2025, and an archive date of July 5, 2025. The award ceiling for this grant is $275,000. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/pa-files/PAR-23-139.html](http://grants.nih.gov/grants/guide/pa-files/PAR-23-139.html). For any inquiries, individuals can contact NIH Grants Information at grantsinfo@nih.gov.
CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)". This grant aims to support the early-stage development of therapeutics that can mitigate the adverse health effects resulting from toxic chemical exposure. The service/item being procured is the development of therapeutics to combat chemical threats, which include toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. These chemical threats encompass specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The grant seeks to validate therapeutic targets and conduct preclinical characterization of lead compounds. The UG3 phase of the grant supports target validation and characterization of initial lead compound(s), while the UH3 phase focuses on candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. By the end of the funding period, projects are expected to deliver at least one well-characterized therapeutic candidate. The grant is a cooperative agreement and falls under the category of funding activity related to health. There is no cost sharing or matching requirement for this grant opportunity. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. territories or possessions. Non-domestic (non-U.S.) entities and components are not eligible to apply. The grant has a closing date of October 17, 2024, and an award ceiling of $350,000. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/pa-files/PAR-22-209.html](http://grants.nih.gov/grants/guide/pa-files/PAR-22-209.html). For any inquiries, the NIH OER Webmaster can be contacted at OERWebmaster03@od.nih.gov.
Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health is offering a limited competition grant opportunity titled "Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)". This grant aims to support projects that enhance our understanding of chemical threats to the skin. The grant does not allow for clinical trials. The total program funding is estimated to be $2,500,000, with an award ceiling of $225,000. It is expected that 8 awards will be granted. The closing date for applications is September 7, 2024. Eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and Historically Black Colleges and Universities. Non-domestic entities and components are not eligible to apply. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAS-21-245.html](http://grants.nih.gov/grants/guide/pa-files/PAS-21-245.html). For any issues or inquiries, please contact the NIH OER Webmaster at grantsinfo@nih.gov.
Notice of Intent to Publish a Funding Opportunity Announcement for CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is planning to publish a funding opportunity announcement for the Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System. This grant aims to support basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system. The research projects funded by this grant are expected to generate data that elucidate mechanisms of toxicity, identify new manifestations of toxic exposures, and identify potential targets for therapeutic development. The funding opportunity is expected to be published in Winter 2024, with an application due date in Spring 2024. The grant will utilize the R01 activity code.